Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer
作者： R Watanabe , Y Takiguchi , T Moriya , S Oda , K Kurosu
关键词: Surgery 、 Combination chemotherapy 、 Lung cancer 、 Etoposide 、 Hemodialysis 、 Pharmacokinetics 、 Medicine 、 Cisplatin 、 Chemotherapy 、 Urology 、 Small-cell carcinoma
摘要: Cancer chemotherapy for haemodialysis patients has never been established. To elucidate the feasibility of cisplatin-based combination with lung cancer, a dose escalation study was conducted. Five cancer were treated cisplatin and etoposide. A starting 40 mg m(-2) on day 1 50 etoposide days 1, 3 5 administered as first course patient. Membrane regularly performed three times week soon after completion therapy. By monitoring toxicity pharmacokinetics data, escalated by patient Dose completed two resulting in full-dose consisting 80 100 5. Multiple courses to other patients. Toxicity manageable tolerable all. Pharmacokinetics data comparable those from normal renal function, except potential long-lasting higher levels free platinum insufficiency group. In conclusion, this standard-dose feasible even
nature.com
sci-hub.se 参考文章(20)
Wakui A, Konno K, Sakata Y, Kano A, Kawamoto K, Sato S, Hashimoto S, Yokoyama M, Yoshida Y, Takahashi H, [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 13, pp. 319- 329 ,(1986)
H Yanagawa, S Okada, H Bando, H Sumitani, Y Takishita, Carboplatin-based chemotherapy in patients undergoing hemodialysis. Anticancer Research. ,vol. 16, pp. 533- 535 ,(1996)
W K Evans, F A Shepherd, R Feld, D Osoba, P Dang, G Deboer, VP-16 and cisplatin as first-line therapy for small-cell lung cancer. Journal of Clinical Oncology. ,vol. 3, pp. 1471- 1477 ,(1985) , 10.1200/JCO.1985.3.11.1471
Clinton F. Stewart, Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemotherapy and Pharmacology. ,vol. 34, ,(1994) , 10.1007/BF00684868
Robert A Wolf, Elisabeth Jones, Alex PS Dsiney, Douglas Briggs, Margaret McCredie, Peter Boyle, Patrick Maisonneuve, Lawrence Agodoa, Ryszard Gellert, John H Stewart, Gheardo Buccianti, Albert B Lowenfels, Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. The Lancet. ,vol. 354, pp. 93- 99 ,(1999) , 10.1016/S0140-6736(99)06154-1
MW English, SP Lowis, B Peng, A Boddy, DR Newell, L Price, ADJ Pearson, Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis British Journal of Cancer. ,vol. 73, pp. 776- 780 ,(1996) , 10.1038/BJC.1996.135
David H. Johnson, Evolution of Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer: A Historical Perspective and The Eastern Cooperative Oncology Group Experience Chest. ,vol. 117, pp. 133- ,(2000) , 10.1378/CHEST.117.4_SUPPL_1.133S
Hansjörg Sauer, Klaus Füger, Matthias Blumenstein, Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo. Cancer Treatment Reviews. ,vol. 17, pp. 293- 300 ,(1990) , 10.1016/0305-7372(90)90060-S
Jonathan G. Fox, David J. Kerr, Michael Soukop, John G. Farmer, Marjorie E. M. Allison, Successful use of cisplatin to treat metastatic seminoma during cisplatin-induced acute renal failure Cancer. ,vol. 68, pp. 1720- 1723 ,(1991) , 10.1002/1097-0142(19911015)68:8<1720::AID-CNCR2820680812>3.0.CO;2-A
R.J. Strife, L. Jardine, M. Colvin, Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 224, pp. 168- 174 ,(1981) , 10.1016/S0378-4347(00)80153-X